Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AtriCure (ATRC) Receivables (2016 - 2025)

AtriCure (ATRC) has disclosed Receivables for 16 consecutive years, with $66.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables rose 10.46% to $66.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $66.7 million, a 10.46% increase, with the full-year FY2025 number at $66.7 million, up 10.46% from a year prior.
  • Receivables was $66.7 million for Q4 2025 at AtriCure, up from $63.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $66.7 million in Q4 2025 to a low of $29.7 million in Q1 2021.
  • A 5-year average of $49.0 million and a median of $49.9 million in 2023 define the central range for Receivables.
  • Peak YoY movement for Receivables: skyrocketed 47.8% in 2021, then rose 6.56% in 2024.
  • AtriCure's Receivables stood at $33.0 million in 2021, then grew by 29.29% to $42.7 million in 2022, then rose by 22.97% to $52.5 million in 2023, then grew by 14.93% to $60.3 million in 2024, then rose by 10.46% to $66.7 million in 2025.
  • Per Business Quant, the three most recent readings for ATRC's Receivables are $66.7 million (Q4 2025), $63.0 million (Q3 2025), and $66.0 million (Q2 2025).